Boston, MA (PressExposure) September 20, 2012 -- Lyn H. Jones, Senior Director and Head of Chemical Biology & Rare Diseases Chemistry at Pfizer will give a featured presentation on "Applying Kinase Chemical Biology to Advance Drug Discovery" at the Protein Kinases and Drug Design conference taking place on Nov 8-9, 2012 in Boston, MA.
Significant advances need to be made in kinase drug discovery, from our ability to choose the appropriate biological mechanism and therapeutic modality at the start of this process, through to understanding the context dependence and pharmacokinetic-pharmacodynamic relationships of agents in the clinic. In his presentation, Dr. Jones will detail examples of his group's application and development of chemical biology techniques in kinase drug discovery research. Other approaches to advance translational medicine through occupancy biomarker technologies will also be presented.
Benefits of his presentation include:
Design, synthesis and application of kinase chemical biology probes
Analysis of the kinase cysteinome
New opportunities to apply chemical biology techniques to understand pathological chemistries
In-cell proteomics versus cell lysate
Lyn Jones received his undergraduate education at the University of Bath and then completed PhD studies with Prof. Alan Armstrong at the University of Nottingham in synthetic organic chemistry. He then started his post doctorate research with Prof. Kim Janda at The Scripps Research Institute, California in the areas of chemical biology and biochemistry. In 2001, he joined Pfizer in Sandwich, UK as a medicinal chemistry team leader and his contributions to the early clinical portfolio were recognized with the inaugural Royal Society of Chemistry Young Industrialist of the Year Award in 2009. He recently transferred to Cambridge, Massachusetts to lead the Chemical Biology and Rare Diseases Chemistry groups in Pfizer.
GTC's Protein Kinases and Drug Design conference, one of two parallel tracks of the Cancer Summit - Novel Approaches to Drug Discovery on November 8-9 in Boston, MA, brings together leading experts from the industry and academia to collaborate on the latest cutting edge research on drug design and development, selective and non-selective kinases inhibitors, hit and target identification, oncology kinases and inhibitors, and other kinases targets. Experts will also share their positive and negative experiences on how predictive preclinical models are with clinical efficacy and toxicology.
For more information, please visit http://www.gtcbio.com